Document Detail


Preliminary Application of a New Bolus Insulin Model for Type 1 Diabetes.
MedLine Citation:
PMID:  21410336     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Background: Previous work derived a theoretically rigorous bolus insulin model. It was shown that the new model predicts insulin response of subjects without diabetes substantially better than the carbohydrate counting method (CHOcm). As most individuals with type 1 diabetes use the CHOcm, this article investigates if the new model can be applied to them. Methods: Equations are derived to characterize a person with type 1 diabetes. These are implemented on a cell phone that calculates bolus insulin dosages. In a small feasibility study the cell phone was used by 11 patients. Basal insulin remained unchanged. The subjects were experienced in the CHOcm and were using it at the start of the study. Continuous glucose monitoring data were recorded to capture blood glucose (BG) control elements such as average BG and tightness of control, as well as hypoglycemic and hyperglycemic events. A new rating method was proposed to estimate BG control. It (or a derivative thereof ) may in the future become a valuable measure of total glycemic control. We used the status quo ante versus status quo approach to find indicative results. BG control for the same group when using CHOcm (status quo ante) was compared with BG control when using the new application (status quo). Results: Patients found the new application on the cell phone practical. Indicative results also showed BG control improvements, although the subjects were more experienced in the CHOcm. Depending on the weights assigned to the underlying control elements an improvement of between 26% and 64% was found. Conclusion: An indicative study (status quo ante vs. status quo) on 11 patients with type 1 diabetes showed that the new method can be practically and successfully applied on a cell phone. Glycemic control even improved. A new BG rating method was proposed. We believe there is enough preliminary indication to warrant a more detailed clinical trial in future by an institution with adequate funds and access to more patients.
Authors:
Ruaan Pelzer; Edward H Mathews; Leon Liebenberg
Related Documents :
10714896 - Paracrine effects of angiotensin-converting-enzyme- and angiotensin-ii-receptor- inhibi...
2943226 - Effect of streptozotocin-induced diabetes and insulin treatment on the synthesis of hex...
1317936 - In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells.
16134756 - The effects of valsartan on lipid profile in normotensive type 2 diabetic patients.
16918196 - Evaluation of asymptomatic central neuropathy in type i diabetes mellitus.
18843446 - Bone biomechanical and histomorphometrical investment in type 2 diabetic goto-kakizaki ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-16
Journal Detail:
Title:  Diabetes technology & therapeutics     Volume:  -     ISSN:  1557-8593     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100889084     Medline TA:  Diabetes Technol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Contracted to the Department of Engineering, North-West University , Pretoria, South Africa .
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic ...
Next Document:  A Novel Approach to Hospital Palliative Care: An Expanded Role for Counselors.